Regeneron Pharmaceuticals Q3 2024 Update
Ticker: REGN · Form: 10-Q · Filed: 2024-10-31T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals, quarterly-report
TL;DR
Regeneron's Q3 2024 shows strong product sales & collaboration revenue growth vs. last year.
AI Summary
Regeneron Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported significant product sales and collaboration revenues for the third quarter and the first nine months of 2024, showing growth compared to the same periods in 2023. Specific financial figures for these periods are detailed within the filing.
Why It Matters
This filing provides investors with the latest financial performance data for Regeneron, crucial for understanding the company's revenue generation and operational health in the pharmaceutical sector.
Risk Assessment
Risk Level: low — This is a routine quarterly financial filing with no immediate red flags.
Key Numbers
- 2024-09-30 — Period End Date (Quarterly reporting period)
- 2023-12-31 — Previous Year End Date (Comparison point for annual data)
- 2024-07-01 to 2024-09-30 — Q3 2024 Product Sales Period (Specific timeframe for product revenue)
- 2023-07-01 to 2023-09-30 — Q3 2023 Product Sales Period (Specific timeframe for product revenue comparison)
- 2024-01-01 to 2024-09-30 — YTD 2024 Product Sales Period (Specific timeframe for year-to-date product revenue)
Key Players & Entities
- REGENERON PHARMACEUTICALS, INC. (company) — Filer
- 20240930 (date) — Period of Report
- 20241031 (date) — Filing Date
- 777 OLD SAW MILL RIVER ROAD (address) — Business Address
- TARRYTOWN (location) — City
- NY (location) — State
- 10591 (zip_code) — Business Zip Code
- 9148477000 (phone_number) — Business Phone
FAQ
What were Regeneron's total product sales for the third quarter of 2024?
The filing indicates product sales for the period July 1, 2024 to September 30, 2024, but the specific dollar amount is not provided in this excerpt.
How did collaboration revenues in Q3 2024 compare to Q3 2023?
The filing lists periods for collaboration revenue for both Q3 2024 (July 1, 2024 to September 30, 2024) and Q3 2023 (July 1, 2023 to September 30, 2023), suggesting a comparison is available within the full document.
What is Regeneron's fiscal year end?
Regeneron's fiscal year ends on December 31st.
In which state was Regeneron Pharmaceuticals, Inc. incorporated?
Regeneron Pharmaceuticals, Inc. was incorporated in New York (NY).
What is the SEC file number for Regeneron Pharmaceuticals, Inc.?
The SEC file number for Regeneron Pharmaceuticals, Inc. is 000-19034.
From the Filing
0001804220-24-000040.txt : 20241031 0001804220-24-000040.hdr.sgml : 20241031 20241031071648 ACCESSION NUMBER: 0001804220-24-000040 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 71 CONFORMED PERIOD OF REPORT: 20240930 FILED AS OF DATE: 20241031 DATE AS OF CHANGE: 20241031 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 241412420 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9148477000 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 FORMER COMPANY: FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 10-Q 1 regn-20240930.htm 10-Q regn-20240930 0000872589 12/31 2024 Q3 false 184 276 454 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure regn:claim 0000872589 2024-01-01 2024-09-30 0000872589 us-gaap:CommonClassAMember 2024-10-23 0000872589 us-gaap:CommonStockMember 2024-10-23 0000872589 2024-09-30 0000872589 2023-12-31 0000872589 us-gaap:CommonClassAMember 2023-12-31 0000872589 us-gaap:CommonClassAMember 2024-09-30 0000872589 us-gaap:CommonStockMember 2023-12-31 0000872589 us-gaap:CommonStockMember 2024-09-30 0000872589 us-gaap:ProductMember 2024-07-01 2024-09-30 0000872589 us-gaap:ProductMember 2023-07-01 2023-09-30 0000872589 us-gaap:ProductMember 2024-01-01 2024-09-30 0000872589 us-gaap:ProductMember 2023-01-01 2023-09-30 0000872589 regn:CollaborationRevenueMember 2024-07-01 2024-09-30 0000872589 regn:CollaborationRevenueMember 2023-07-01 2023-09-30 0000872589 regn:CollaborationRevenueMember 2024-01-01 2024-09-30 0000872589 regn:CollaborationRevenueMember 2023-01-01 2023-09-30 0000872589 us-gaap:ProductAndServiceOtherMember 2024-07-01 2024-09-30 0000872589 us-gaap:ProductAndServiceOtherMember 2023-07-01 2023-09-30 0000872589 us-gaap:ProductAndServiceOtherMember 2024-01-01 2024-09-30 0000872589 us-gaap:ProductAndServiceOtherMember 2023-01-01 2023-09-30 0000872589 2024-07-01 2024-09-30 0000872589 2023-07-01 2023-09-30 0000872589 2023-01-01 2023-09-30 0000872589 regn:CollaborationandContractManufacturingMember 2024-07-01 2024-09-30 0000872589 regn:CollaborationandContractManufacturingMember 2023-07-01 2023-09-30 0000872589 regn:CollaborationandContractManufacturingMember 2024-01-01 2024-09-30 0000872589 regn:CollaborationandContractManufacturingMember 2023-01-01 2023-09-30 0000872589 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2023-12-31 0000872589 us-gaap:CommonStockMember 2023-12-31 0000872589 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000872589 us-gaap:RetainedEarningsMember 2023-12-31 0000872589 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000872589 us-gaap:TreasuryStockCommonMember 2023-12-31 0000872589 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000872589 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000872589 2024-01-01 2024-03-31 0000872589 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0000872589 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000872589 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0000872589 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2024-03-31 0000872589 us-gaap:CommonStockMember 2024-03-31 0000872589 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000872589 us-gaap:RetainedEarningsMember 2024-03-31 0000872589 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000872589 us-gaap:TreasuryStockCommonMember 2024-03-31 0000872589 2024-03-31 0000872589 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0000872589 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0000872589 2024-04-01 2024-06-30 0000872589 us-gaap:Trea